Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
70
EBS Quote, Financials, Valuation and Earnings
Last price:
$12.06
Seasonality move
:
3.87%
Day range:
$11.52 - $12.28
52-week range:
$4.02 - $13.41
Dividend yield:
0%
P/E ratio:
8.96x
P/S ratio:
0.82x
P/B ratio:
1.05x
Volume:
888.7K
Avg. volume:
1.3M
1-year change:
27.78%
Market cap:
$609.2M
Revenue:
$1B
EPS (TTM):
$1.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
$199M | -$0.12 | 11.71% | -94.67% | $13.50 |
|
BDTX
Black Diamond Therapeutics, Inc.
|
-- | -$0.23 | -100% | -43.34% | $9.25 |
|
GOVX
GeoVax Labs, Inc.
|
-- | -- | -100% | -- | $9.63 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
SIGA
SIGA Technologies, Inc.
|
-- | -- | -- | -- | -- |
|
TNXP
Tonix Pharmaceuticals Holding Corp.
|
$2.3M | -$2.75 | -18.5% | -90.25% | $67.67 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
$11.60 | $13.50 | $609.2M | 8.96x | $0.00 | 0% | 0.82x |
|
BDTX
Black Diamond Therapeutics, Inc.
|
$2.71 | $9.25 | $154.4M | 7.47x | $0.00 | 0% | 2.21x |
|
GOVX
GeoVax Labs, Inc.
|
$0.40 | $9.63 | $11.9M | -- | $0.00 | 0% | 1.74x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.06 | $0.85 | $133.6M | 1.78x | $0.80 | 0% | 2.06x |
|
SIGA
SIGA Technologies, Inc.
|
$6.24 | -- | $446.9M | 5.99x | $0.60 | 0% | 2.59x |
|
TNXP
Tonix Pharmaceuticals Holding Corp.
|
$17.78 | $67.67 | $130.8M | -- | $0.00 | 0% | 9.58x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
53.53% | 4.454 | 144.36% | 2.93x |
|
BDTX
Black Diamond Therapeutics, Inc.
|
13.49% | 4.929 | 9.11% | 8.72x |
|
GOVX
GeoVax Labs, Inc.
|
-- | 1.075 | -- | 2.75x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
SIGA
SIGA Technologies, Inc.
|
0.43% | 1.632 | 0.13% | 7.02x |
|
TNXP
Tonix Pharmaceuticals Holding Corp.
|
0.18% | -3.103 | 0.24% | 9.28x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
$129.1M | $76.8M | 6.29% | 14.25% | 33.23% | -$5.7M |
|
BDTX
Black Diamond Therapeutics, Inc.
|
-$86K | -$11M | 15.62% | 18.5% | 77.9% | -$7.9M |
|
GOVX
GeoVax Labs, Inc.
|
-$16.8K | -$6.4M | -433.69% | -433.69% | -635.8% | -$6.2M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
SIGA
SIGA Technologies, Inc.
|
$1.6M | -$10.2M | 36.5% | 36.71% | -390.18% | -$10.1M |
|
TNXP
Tonix Pharmaceuticals Holding Corp.
|
$1.5M | -$33.1M | -61.13% | -62.54% | -1005.08% | -$31.5M |
Emergent BioSolutions, Inc. vs. Competitors
-
Which has Higher Returns EBS or BDTX?
Black Diamond Therapeutics, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of 80.77%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Black Diamond Therapeutics, Inc.'s return on equity of 18.5%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B BDTXBlack Diamond Therapeutics, Inc.-- -$0.15 $145.8M -
What do Analysts Say About EBS or BDTX?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 16.38%. On the other hand Black Diamond Therapeutics, Inc. has an analysts' consensus of $9.25 which suggests that it could grow by 241.33%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 BDTXBlack Diamond Therapeutics, Inc.6 1 0 -
Is EBS or BDTX More Risky?
Emergent BioSolutions, Inc. has a beta of 2.318, which suggesting that the stock is 131.831% more volatile than S&P 500. In comparison Black Diamond Therapeutics, Inc. has a beta of 3.331, suggesting its more volatile than the S&P 500 by 233.083%.
-
Which is a Better Dividend Stock EBS or BDTX?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Black Diamond Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Black Diamond Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or BDTX?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than Black Diamond Therapeutics, Inc. quarterly revenues of --. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than Black Diamond Therapeutics, Inc.'s net income of -$8.5M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.96x while Black Diamond Therapeutics, Inc.'s PE ratio is 7.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.82x versus 2.21x for Black Diamond Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.82x 8.96x $231.1M $51.2M BDTXBlack Diamond Therapeutics, Inc.2.21x 7.47x -- -$8.5M
-
Which has Higher Returns EBS or GOVX?
GeoVax Labs, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of -630.04%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat GeoVax Labs, Inc.'s return on equity of -433.69%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M -
What do Analysts Say About EBS or GOVX?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 16.38%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $9.63 which suggests that it could grow by 2302.05%. Given that GeoVax Labs, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 GOVXGeoVax Labs, Inc.4 0 0 -
Is EBS or GOVX More Risky?
Emergent BioSolutions, Inc. has a beta of 2.318, which suggesting that the stock is 131.831% more volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.638, suggesting its more volatile than the S&P 500 by 263.848%.
-
Which is a Better Dividend Stock EBS or GOVX?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or GOVX?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than GeoVax Labs, Inc. quarterly revenues of --. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.96x while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.82x versus 1.74x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.82x 8.96x $231.1M $51.2M GOVXGeoVax Labs, Inc.1.74x -- -- -$6.3M
-
Which has Higher Returns EBS or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of -255.85%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About EBS or NBY?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 16.38%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that Emergent BioSolutions, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Emergent BioSolutions, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is EBS or NBY More Risky?
Emergent BioSolutions, Inc. has a beta of 2.318, which suggesting that the stock is 131.831% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock EBS or NBY?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or NBY?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.96x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.82x versus 2.06x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.82x 8.96x $231.1M $51.2M NBYNovaBay Pharmaceuticals, Inc.2.06x 1.78x $521K -$1.3M
-
Which has Higher Returns EBS or SIGA?
SIGA Technologies, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of -242.97%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat SIGA Technologies, Inc.'s return on equity of 36.71%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B SIGASIGA Technologies, Inc.61.75% -$0.09 $204.4M -
What do Analysts Say About EBS or SIGA?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 16.38%. On the other hand SIGA Technologies, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Emergent BioSolutions, Inc. has higher upside potential than SIGA Technologies, Inc., analysts believe Emergent BioSolutions, Inc. is more attractive than SIGA Technologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 SIGASIGA Technologies, Inc.0 0 0 -
Is EBS or SIGA More Risky?
Emergent BioSolutions, Inc. has a beta of 2.318, which suggesting that the stock is 131.831% more volatile than S&P 500. In comparison SIGA Technologies, Inc. has a beta of 0.980, suggesting its less volatile than the S&P 500 by 1.989%.
-
Which is a Better Dividend Stock EBS or SIGA?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SIGA Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.60 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. SIGA Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or SIGA?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than SIGA Technologies, Inc. quarterly revenues of $2.6M. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than SIGA Technologies, Inc.'s net income of -$6.4M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.96x while SIGA Technologies, Inc.'s PE ratio is 5.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.82x versus 2.59x for SIGA Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.82x 8.96x $231.1M $51.2M SIGASIGA Technologies, Inc.2.59x 5.99x $2.6M -$6.4M
-
Which has Higher Returns EBS or TNXP?
Tonix Pharmaceuticals Holding Corp. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of -972.95%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Tonix Pharmaceuticals Holding Corp.'s return on equity of -62.54%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B TNXPTonix Pharmaceuticals Holding Corp.44.44% -$3.59 $231.6M -
What do Analysts Say About EBS or TNXP?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 16.38%. On the other hand Tonix Pharmaceuticals Holding Corp. has an analysts' consensus of $67.67 which suggests that it could grow by 280.58%. Given that Tonix Pharmaceuticals Holding Corp. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Tonix Pharmaceuticals Holding Corp. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 TNXPTonix Pharmaceuticals Holding Corp.2 0 0 -
Is EBS or TNXP More Risky?
Emergent BioSolutions, Inc. has a beta of 2.318, which suggesting that the stock is 131.831% more volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding Corp. has a beta of 1.817, suggesting its more volatile than the S&P 500 by 81.674%.
-
Which is a Better Dividend Stock EBS or TNXP?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or TNXP?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than Tonix Pharmaceuticals Holding Corp. quarterly revenues of $3.3M. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than Tonix Pharmaceuticals Holding Corp.'s net income of -$32M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.96x while Tonix Pharmaceuticals Holding Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.82x versus 9.58x for Tonix Pharmaceuticals Holding Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.82x 8.96x $231.1M $51.2M TNXPTonix Pharmaceuticals Holding Corp.9.58x -- $3.3M -$32M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
